PharmAbcine Inc.

PharmAbcine Inc., a clinical-stage biotech company, develops human therapeutic monoclonal antibody (mAb) for the treatment of neovascular disorders, tumors, and other medically unmet diseases. It provides therapeutic antibodies for various spectrum of indications from oncology, immuno-oncology, ophthalmology, and pulmonology. The company also develops TTAC0001, an anti-angiogenic that neutralizes the VEGF/VEGFR2 pathway; PMC-309, a monoclonal antibody that targets the negative immune checkpoint human VISTA; PMC-402, a monoclonal antibody that targets the human TIE2 that regulated activation, proliferation, and repolarization for solid tumors; and PMC-403, a monoclonal antibody that targets the human TIE2, which regulate the angiogenesis and vessel maturation in endothelial cells. In addition, its pipeline products for the development new candidates such as PMC-005BL, PMC-122, PMC-401, and PMC-401s. The company has a strategic partnership with Samsung Biologics Co.,Ltd. for the development and manufacturing of oncology and neovascular treatment; a clinical trial collaboration with MSD for the Phase II study in mTNBC; and a research collaboration agreement with LegoChem Biosciences Inc. (LCB) to provide PMC-403, a preclinical pipeline to LCB for combination research using PMC-403 and LCB's ADC for solid tumors. PharmAbcine Inc. is was founded in 2008 and based in Daejeon, South Korea.